Reported 1 day ago
GRAIL, Inc. (NASDAQ:GRAL) has emerged as one of the top-performing IPOs in recent years, showcasing significant growth after reporting $35.5 million in revenue for Q2 2025, buoyed by high demand for its Galleri tests. Strong partnerships with healthcare systems and positive research updates further bolster its outlook. Notably, executives have been active in selling shares, with a 169.02% increase in value since its IPO on June 25, 2024, reflecting strong market confidence in the company's mission to detect cancer early.
Source: YAHOO